Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: A single institution retrospective study

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 5, 2014, Pages 424-430.e1

  Scott, Emma C ^a   Heitner, Stephen B ^b   Dibb, William ^a   Meyers, Gabrielle ^a   Smith, Stephen D ^a   Abar, Farnoush ^a   Kovacsovics, Tibor ^a   Perez Avraham, Galit ^a   Stentz, Alex ^a   Frires, Rachel ^a   Dibb, James ^a   Maziarz, Richard T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Amyloid; Bortezomib induction; Stem cell transplantation

Indexed keywords

BORTEZOMIB; BRAIN NATRIURETIC PEPTIDE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; M PROTEIN; MELPHALAN; PLERIXAFOR; THALIDOMIDE; TROPONIN I; AMYLOID PROTEIN; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; IMMUNOGLOBULIN LIGHT CHAIN; MYELOABLATIVE AGENT; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE;

ABLATION THERAPY; ADULT; AGED; AMYLOIDOSIS; APHERESIS; ARTICLE; ARTIFICIAL HEART PACEMAKER; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DISEASE SEVERITY; DRUG MEGADOSE; DRUG TOLERABILITY; EXSANGUINATION; FEMALE; FOLLOW UP; HEART AMYLOIDOSIS; HEART MUSCLE CONDUCTION DISTURBANCE; HEART TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LIGHT CHAIN; LIGHT CHAIN AMYLOIDOSIS; MALE; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT PREFERENCE; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SEPSIS; SERUM; SPLEEN RUPTURE; STEM CELL MOBILIZATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; CARDIOMYOPATHIES; COMPLICATION; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; EVALUATION STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; KIDNEY DISEASES; MIDDLE AGED; REMISSION; TREATMENT OUTCOME;

ADULT; AGED; AMYLOIDOGENIC PROTEINS; AMYLOIDOSIS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CARDIOMYOPATHIES; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; MALE; MELPHALAN; MIDDLE AGED; MYELOABLATIVE AGONISTS; PROTEASOME INHIBITORS; PYRAZINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; THALIDOMIDE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84908667921     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2014.02.003     Document Type: Article

References (32)

1. M.A. Gertz Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management Am J Hematol 86 2011 180 186
2. S. Kumar, A. Dispenzieri, and M.Q. Lacy Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements J Clin Oncol 30 2012 989 995
3. S.K. Kumar, M.A. Gertz, and M.Q. Lacy Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score Mayo Clin Proc 86 2011 12 18
4. S. Cordes, A. Dispenzieri, and M.Q. Lacy Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis Cancer 118 2012 6105 6109
5. V. Sanchorawala, M. Skinner, K. Quillen, K.T. Finn, G. Doros, and D.C. Seldin Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Blood 110 2007 3561 3563
6. M.A. Gertz, M.Q. Lacy, and A. Dispenzieri Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report Leuk Lymphoma 51 2010 2181 2187
7. A. Jaccard, P. Moreau, and V. Leblond High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis N Engl J Med 357 2007 1083 1093
8. M.A. Gertz, M.Q. Lacy, and A. Dispenzieri Refinement in patient selection to reduce treatment-related mortality from SCT in amyloidosis Bone Marrow Transplant 48 2012 557 561
9. M.A. Gertz, F.K. Buadi, and S.R. Hayman Treatment of immunoglobulin light chain (primary or AL) amyloidosis Oncology (Williston Park) 25 2011 620 626
10. M.A. Gertz, M.Q. Lacy, and A. Dispenzieri Risk-adjusted manipulation of melphalan dose before stem cell transplantation in patients with amyloidosis is associated with a lower response rate Bone Marrow Transplant 34 2004 1025 1031
11. A.D. Cohen, P. Zhou, and J. Chou Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial Br J Haematol 139 2007 224 233
12. A. Dispenzieri, M.A. Gertz, and R.A. Kyle Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood 104 2004 1881 1887
13. A. Dispenzieri, R.A. Kyle, and M.Q. Lacy Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study Blood 103 2004 3960 3963
14. M.A. Gertz, M.Q. Lacy, and A. Dispenzieri Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response Haematologica 92 2007 1415 1418
15. H. Landau, H. Hassoun, and M.A. Rosenzweig Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis Leukemia 27 2013 823 828
16. American Society of Hematology. Atlanta, Georgia, Dec 8-11, 2012. Blood (ASH Annual Meeting Abstracts) 2012; 120:Abstract 2019.
17. M.A. Gertz, R. Comenzo, and R.H. Falk Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004 Am J Hematol 79 2005 319 328
18. M. Gertz Definition of organ involvement and response to treatment in AL amyloidosis: an updated consensus opinion Amyloid 17 suppl 1 2010 48 49
19. G. Palladini, A. Dispenzieri, and M.A. Gertz New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes J Clin Oncol 30 2012 4541 4549
20. A. Dispenzieri, M.A. Gertz, and R.A. Kyle Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis J Clin Oncol 22 2004 3751 3757
21. P.A. McCullough, R.M. Nowak, and J. McCord B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study Circulation 106 2002 416 422
22. M.T. Cibeira, V. Sanchorawala, and D.C. Seldin Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients Blood 118 2011 4346 4352
23. M.A. Gertz, M.Q. Lacy, and A. Dispenzieri Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006 Bone Marrow Transplant 46 2011 970 975
24. V.H. Jimenez-Zepeda, N. Franke, and D.E. Reece Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution Br J Haematol 164 2014 722 728
25. J.L. Harousseau, H. Avet-Loiseau, and M. Attal Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials J Clin Oncol 27 2009 5720 5726
26. A.A. Chanan-Khan, and S. Giralt Importance of achieving a complete response in multiple myeloma, and the impact of novel agents J Clin Oncol 28 2010 2612 2624
27. D.E. Reece, U. Hegenbart, and V. Sanchorawala Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study Blood 118 2011 865 873
28. J.R. Mikhael, S.R. Schuster, and V.H. Jimenez-Zepeda Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis Blood 119 2012 4391 4394
29. V. Sanchorawala, D.G. Wright, and D.C. Seldin High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial Bone Marrow Transplant 33 2004 381 388
30. A. Hacihanefioglu, P. Tarkun, and E. Gonullu Acute severe cardiac failure in a myeloma patient due to proteasome inhibitor bortezomib Int J Hematol 88 2008 219 222
31. J. Voortman, and G. Giaccone Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report BMC Cancer 6 2006 129
32. P.G. Richardson, P. Sonneveld, and M.W. Schuster Bortezomib or high-dose dexamethasone for relapsed multiple myeloma N Engl J Med 352 2005 2487 2498